Sanofi SA (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 223   

Articles published

SNY 51.29 +0.74 (1.46%)
price chart
Sanofi SA (ADR) (SNY) Diabetes Drug Sales Disappoint; Trend Expected To ...
Sanofi SA (ADR) (NYSE:SNY) announced that the company's diabetes products saw a larger-than-expected drop in sales due to lower pricing of the company's star drug, Lantus.
Sanofi SA (ADR) Decides Against Discounting Toujeo More Than Lantus
Sanofi SA (ADR) (NYSE:SNY) has declared it will not offer steeper rebates for its newly approved insulin product Toujeo than those already existing on its older blockbuster version Lantus, soon to go off-patent in the US and EU.
Sanofi SA (ADR) (SNY) Upgraded To Outperform By Leerink Partners
Sanofi SA (ADR) (NYSE:SNY) stock was upgraded from a Market Perform rating to an Outperform rating by analysts at Leerink Swann & Company in a research report issued to clients on Tuesday.
Leerink Swann & Company promoted Sanofi SA (ADR) (NYSE:SNY) to an Outplay  Stocks.org
Bayer's Brandicourt To Be Named Sanofi SA (ADR) CEO - Reports
Sanofi SA (ADR) (NYSE:SNY) has been searching for a candidate to replace its ousted Chief Executive Officer Chris Viehbacher ever since October last year; Olivier Brandicourt, head of Bayer AG (ADR)'s (OTCMKTS:BAYRY) healthcare business, might put ...
Sanofi SA (ADR) May Launch Toujeo In The US On Monday
Sanofi SA ADR (NYSE:SNY) plans to launch its new insulin, Toujeo, for the treatment of diabetic patients in the US as early as this Monday, people familiar with the matter said.
Why Sanofi SA (ADR) Doesn't Consider Acquisitions Essential For Future Growth
The French pharmaceutical giant, Sanofi SA (ADR) (NYSE:SNY), after considering various acquisition options, has reached the conclusion that takeovers and various deal-making opportunities would not be the most essential growth driver for the company in ...
Sanofi SA (ADR), Evotec Enter Into �250 million Strategic Alliance
Sanofi SA ADR (NYSE:SNY) on Saturday announced to transfer its research facility in Toulouse, France to Evotec AG ADR (OTCMKTS:EVTCY) in a deal worth �250 million.
Sanofi SA (ADR): Differing Regulatory Decisions Harm Global Drug Research
The marked difference in the timings of regulatory decisions worldwide regarding new medicines is a pressing issue affecting the profitability of pharmaceutical research, as discussed by Elias Zerhouni, head of research at Sanofi SA (ADR) (NYSE:SNY) on ...
VBI Vaccines Inc. (VBIV) Shares Soar After Partnership With Sanofi SA (ADR)
VBI Vaccines Inc. (NASDAQ:VBIV) jumped more than 20% in after-hours trade on Monday, following an announcement that the vaccines division of Sanofi SA (ADR) (NYSE:SNY), Sanofi Pasteur, will apply VBI's LPV� (Lipid Particle Vaccine) formulation ...
Sanofi SA (ADR) New CEO To Focus On US Market
Sanofi SA's (ADR) (NYSE:SNY) former CEO Mr. Viehbacher was sacked primarily because he had a different work ethic than the company's board.
Sanofi Appoints Olivier Brandicourt CEO -- 2nd Update  Nasdaq